Richard Johnston and Elizabeth D. Krell, Ph.D. are Retiring from the
Board of Directors in May
MASON, Ohio--(BUSINESS WIRE)--Feb. 20, 2018--
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage management, today
announced that Scott Drake has been named Board Chairman, effective at
the annual meeting in May of this year. Concurrent with this
appointment, Richard Johnston, the company’s current chairman, and
Elizabeth D. Krell, Ph.D. are planning to retire from the Board of
Directors and are not standing for re-election.
“Scott’s proven executive experience managing growing businesses,
achieving sustainable revenue growth and driving operational
improvements have been invaluable to our organization over the past four
years. I am delighted that AtriCure can further benefit from his
leadership in his new role as Board Chairman” stated Richard Johnson,
Chairman of AtriCure.
Mr. Drake has served as one of the company’s directors since September
2013. He was most recently the President and Chief Executive Officer of
Spectranetics Corporation. Spectranetics, acquired by Philips in August
of 2017, develops, manufactures and distributes single-use medical
devices used in minimally invasive procedures within the cardiovascular
system. Prior to joining Spectranetics, Mr. Drake served as Senior Vice
President, Operations of DaVita, Inc., a leading U.S. provider of kidney
care and dialysis, from 2009 to August 2011. Previously, Mr. Drake held
several positions of increasing responsibility within various healthcare
business units at Covidien, Plc over a period of 17 years, including:
Global Business Unit President, Respiratory and Monitoring Solutions,
President, Valleylab (re-named as the Surgical Solutions Group) and Vice
President and General Manager, Critical Care. Mr. Drake is an EY 2014
Entrepreneur of The Year™. He also serves on the Board of Directors for
Just Right Surgical and the Medical Device Manufacturers Association
(MDMA). Mr. Drake holds a B.S. in Business Administration from Miami
University of Ohio.
“I would like to acknowledge Dick and Liz for their many contributions
to our organization during their respective tenures on our Board,”
stated Mike Carrel, President and Chief Executive Officer of AtriCure.
“Dick’s direction as our longstanding Chairman has been critical in
navigating the company to our leading position in the market today. From
the early days of the company’s inception, through a successful public
offering, to bringing me on board as CEO, to managing the board
composition, and to helping reshape the company over the past five plus
years, Dick’s impact will be felt for many years to come. Liz has been
instrumental in our regulatory and clinical strategies over the past ten
years, bringing expertise in risk assessment and healthcare compliance.
On behalf of our entire board, I thank them both for their truly
valuable service and guidance.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial
Appendage Exclusion System products are the most widely sold LAA
management devices worldwide, with more than 125,000 implanted to date.
For more information, visit AtriCure.com or follow us on Twitter
View source version on businesswire.com: http://www.businesswire.com/news/home/20180220005826/en/
Source: AtriCure, Inc.
Corporate Marketing and Communications
Senior Vice President and Chief